BAY W 9798

Drug Profile

BAY W 9798

Latest Information Update: 29 May 1995

Price : $50

At a glance

  • Originator Bayer
  • Class Anti-inflammatories; Dihydropyridines; Peripheral vasodilators; Vascular disorder therapies
  • Mechanism of Action Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Peripheral vascular disorders

Most Recent Events

  • 29 May 1995 Discontinued-II for Peripheral vascular disorders in Germany (Unknown route)
  • 29 May 1995 Discontinued-II for Peripheral vascular disorders in USA (Unknown route)
  • 29 May 1995 Discontinued-I for Peripheral vascular disorders in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top